 The National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines has been updated for breast cancer treatment and includes two essential changes for Puma Biotechnology Inc NASDAQ: PBYI Nerlynx neratinib. The first update added Nerlynx to the body of the guidelines for treating adjuvant HER2-positive Breast Cancer, with a recommendation for considering extended adjuvant neratinib for patients with HR-positive, HER2-positive disease with a perceived high risk of recurrence. 